The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising biomarker for treatment efficacy. This study aims to optimize PDO drug screening methods for correlation with patient response and explore the potential to predict responses to standard chemotherapies.

Discover more from HUB:

Explore our organoid screening platform 

discover more

Discover other publications on patient-derived organoids.

browse now